Nicolas Perrot1,2, Sébastien Thériault1,3, Christian Dina4, Hao Yu Chen5, S Matthijs Boekholdt6, Sidwell Rigade4, Audrey-Anne Després1,2, Anthony Poulin1, Romain Capoulade4, Thierry Le Tourneau4, David Messika-Zeitoun7,8, Mikaël Trottier1, Michel Tessier1, Jean Guimond1, Maxime Nadeau1, James C Engert5, Kay-Tee Khaw9, Nicholas J Wareham10, Marc R Dweck11, Patrick Mathieu1,12, Philippe Pibarot1,2, Jean-Jacques Schott4, George Thanassoulis5, Marie-Annick Clavel1,2, Yohan Bossé1,13, Benoit J Arsenault1,2. 1. Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec City, Québec, Canada. 2. Department of Medicine, Faculty of Medicine, Université Laval, Québec City, Québec, Canada. 3. Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec City, Québec, Canada. 4. L'Institut du Thorax, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Université de Nantes, Nantes, France. 5. McGill University Health Center Research Institute, Montreal, Québec, Canada. 6. Department of Cardiology, Academic Medical Center, Amsterdam, the Netherlands. 7. Department of Cardiology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France. 8. University of Ottawa Heart Institute, Ottawa, Ontario, Canada. 9. Medical Research Council Epidemiology Unit, Cambridge, United Kingdom. 10. Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom. 11. Centre for Cardiovascular Science, University of Edinburgh, United Kingdom. 12. Department of Surgery, Faculty of Medicine, Université Laval, Québec City, Québec, Canada. 13. Department of Molecular Medicine, Faculty of Medicine, Université Laval, Québec City, Québec, Canada.
Abstract
Importance: Genetic variants at the LPA locus are associated with both calcific aortic valve stenosis (CAVS) and coronary artery disease (CAD). Whether these variants are associated with CAVS in patients with CAD vs those without CAD is unknown. Objective: To study the associations of LPA variants with CAVS in a cohort of patients undergoing heart surgery and LPA with CAVS in patients with CAD vs those without CAD and to determine whether first-degree relatives of patients with CAVS and high lipoprotein(a) (Lp[a]) levels showed evidence of aortic valve microcalcification. Design, Setting, and Participants: This genetic association study included patients undergoing cardiac surgery from the Genome-Wide Association Study on Calcific Aortic Valve Stenosis in Quebec (QUEBEC-CAVS) study and patients with CAD, patients without CAD, and control participants from 6 genetic association studies: the UK Biobank, the European Prospective Investigation of Cancer (EPIC)-Norfolk, and Genetic Epidemiology Research on Aging (GERA) studies and 3 French cohorts. In addition, a family study included first-degree relatives of patients with CAVS. Data were collected from January 1993 to September 2018, and analysis was completed from September 2017 to September 2018. Exposures: Case-control studies. Main Outcomes and Measures: Presence of CAVS according to a weighted genetic risk score based on 3 common Lp(a)-raising variants and aortic valve microcalcification, defined as the mean tissue to background ratio of 1.25 or more, measured by fluorine 18-labeled sodium fluoride positron emission tomography/computed tomography. Results: This study included 1009 individuals undergoing cardiac surgery and 1017 control participants in the QUEBEC-CAVS cohort; 3258 individuals with CAVS and CAD, 41 100 controls with CAD, 2069 individuals with CAVS without CAD, and 380 075 control participants without CAD in the UK Biobank, EPIC-Norfolk, and GERA studies and 3 French cohorts combined; and 33 first-degree relatives of 17 patients with CAVS and high Lp(a) levels (≥60 mg/dL) and 23 control participants with normal Lp(a) levels (<60 mg/dL). In the QUEBEC-CAVS study, each SD increase of the genetic risk score was associated with a higher risk of CAVS (odds ratio [OR], 1.35 [95% CI, 1.10-1.66]; P = .003). Each SD increase of the genetic risk score was associated with a higher risk of CAVS in patients with CAD (OR, 1.30 [95% CI, 1.20-1.42]; P < .001) and without CAD (OR, 1.33 [95% CI, 1.14-1.55]; P < .001). The percentage of individuals with a tissue to background ratio of 1.25 or more or CAVS was higher in first-degree relatives of patients with CAVS and high Lp(a) (16 of 33 [49%]) than control participants (3 of 23 [13%]; P = .006). Conclusions and Relevance: In this study, a genetically elevated Lp(a) level was associated with CAVS independently of the presence of CAD. These findings support further research on the potential usefulness of Lp(a) cascade screening in CAVS.
Importance: Genetic variants at the LPA locus are associated with both calcific aortic valve stenosis (CAVS) and coronary artery disease (CAD). Whether these variants are associated with CAVS in patients with CAD vs those without CAD is unknown. Objective: To study the associations of LPA variants with CAVS in a cohort of patients undergoing heart surgery and LPA with CAVS in patients with CAD vs those without CAD and to determine whether first-degree relatives of patients with CAVS and high lipoprotein(a) (Lp[a]) levels showed evidence of aortic valve microcalcification. Design, Setting, and Participants: This genetic association study included patients undergoing cardiac surgery from the Genome-Wide Association Study on Calcific Aortic Valve Stenosis in Quebec (QUEBEC-CAVS) study and patients with CAD, patients without CAD, and control participants from 6 genetic association studies: the UK Biobank, the European Prospective Investigation of Cancer (EPIC)-Norfolk, and Genetic Epidemiology Research on Aging (GERA) studies and 3 French cohorts. In addition, a family study included first-degree relatives of patients with CAVS. Data were collected from January 1993 to September 2018, and analysis was completed from September 2017 to September 2018. Exposures: Case-control studies. Main Outcomes and Measures: Presence of CAVS according to a weighted genetic risk score based on 3 common Lp(a)-raising variants and aortic valve microcalcification, defined as the mean tissue to background ratio of 1.25 or more, measured by fluorine 18-labeled sodium fluoride positron emission tomography/computed tomography. Results: This study included 1009 individuals undergoing cardiac surgery and 1017 control participants in the QUEBEC-CAVS cohort; 3258 individuals with CAVS and CAD, 41 100 controls with CAD, 2069 individuals with CAVS without CAD, and 380 075 control participants without CAD in the UK Biobank, EPIC-Norfolk, and GERA studies and 3 French cohorts combined; and 33 first-degree relatives of 17 patients with CAVS and high Lp(a) levels (≥60 mg/dL) and 23 control participants with normal Lp(a) levels (<60 mg/dL). In the QUEBEC-CAVS study, each SD increase of the genetic risk score was associated with a higher risk of CAVS (odds ratio [OR], 1.35 [95% CI, 1.10-1.66]; P = .003). Each SD increase of the genetic risk score was associated with a higher risk of CAVS in patients with CAD (OR, 1.30 [95% CI, 1.20-1.42]; P < .001) and without CAD (OR, 1.33 [95% CI, 1.14-1.55]; P < .001). The percentage of individuals with a tissue to background ratio of 1.25 or more or CAVS was higher in first-degree relatives of patients with CAVS and high Lp(a) (16 of 33 [49%]) than control participants (3 of 23 [13%]; P = .006). Conclusions and Relevance: In this study, a genetically elevated Lp(a) level was associated with CAVS independently of the presence of CAD. These findings support further research on the potential usefulness of Lp(a) cascade screening in CAVS.
Authors: Nicolas Perrot; S Matthijs Boekholdt; Patrick Mathieu; Nicholas J Wareham; Kay-Tee Khaw; Benoit J Arsenault Journal: Int J Cardiol Date: 2018-07-24 Impact factor: 4.164
Authors: Simone L Verweij; Maurice W J de Ronde; Rutger Verbeek; S Matthijs Boekholdt; R Nils Planken; Erik S G Stroes; Sara-Joan Pinto-Sietsma Journal: J Clin Lipidol Date: 2018-02-16 Impact factor: 4.766
Authors: Romain Capoulade; Kwan L Chan; Calvin Yeang; Patrick Mathieu; Yohan Bossé; Jean G Dumesnil; James W Tam; Koon K Teo; Ablajan Mahmut; Xiaohong Yang; Joseph L Witztum; Benoit J Arsenault; Jean-Pierre Després; Philippe Pibarot; Sotirios Tsimikas Journal: J Am Coll Cardiol Date: 2015-09-15 Impact factor: 24.094
Authors: Seyedeh M Zekavat; Sanni Ruotsalainen; Robert E Handsaker; Maris Alver; Jonathan Bloom; Timothy Poterba; Cotton Seed; Jason Ernst; Mark Chaffin; Jesse Engreitz; Gina M Peloso; Ani Manichaikul; Chaojie Yang; Kathleen A Ryan; Mao Fu; W Craig Johnson; Michael Tsai; Matthew Budoff; Ramachandran S Vasan; L Adrienne Cupples; Jerome I Rotter; Stephen S Rich; Wendy Post; Braxton D Mitchell; Adolfo Correa; Andres Metspalu; James G Wilson; Veikko Salomaa; Manolis Kellis; Mark J Daly; Benjamin M Neale; Steven McCarroll; Ida Surakka; Tonu Esko; Andrea Ganna; Samuli Ripatti; Sekar Kathiresan; Pradeep Natarajan Journal: Nat Commun Date: 2018-07-04 Impact factor: 14.919
Authors: Marc R Dweck; H J Khaw; G K Z Sng; E L C Luo; A Baird; M C Williams; P Makiello; S Mirsadraee; N V Joshi; E J R van Beek; N A Boon; J H F Rudd; D E Newby Journal: Eur Heart J Date: 2013-02-07 Impact factor: 29.983
Authors: Michel Pompeu Barros de Oliveira Sá; Luiz Rafael P Cavalcanti; Álvaro M Perazzo; Rafael A F Gomes; Marie-Annick Clavel; Philippe Pibarot; Giuseppe Biondi-Zoccai; Konstantin Zhigalov; Alexander Weymann; Arjang Ruhparwar; Ricardo Carvalho Lima Journal: Curr Atheroscler Rep Date: 2020-01-07 Impact factor: 5.113
Authors: Benoit J Arsenault; William Pelletier; Yannick Kaiser; Nicolas Perrot; Christian Couture; Kay-Tee Khaw; Nicholas J Wareham; Yohan Bossé; Philippe Pibarot; Erik S G Stroes; Patrick Mathieu; Sébastien Thériault; S Matthijs Boekholdt Journal: JAMA Netw Open Date: 2020-02-05